恒瑞快换届了，董事长孙飘扬任期已满

Core Viewpoint - The board of directors of Heng Rui Medicine has announced a postponement of the board election, extending the terms of the current board members and senior management until February 1, 2026, to ensure governance stability and avoid disruptions in research and commercialization processes [1][7][16]. Group 1: Board and Management Changes - The current board of directors, including key executives such as Chairman Sun Piaoyang and President Dai Hongbin, will continue their roles until the new board is elected [3][12]. - The postponement of the board election may be influenced by factors such as strategic continuity, shareholder opinion coordination, and candidate selection [7][16]. - As of February 3, 2023, Heng Rui Medicine's A-share price was 57.47 yuan, with a market capitalization of 381.44 billion yuan, while its Hong Kong stock price was 67 HKD, with a market capitalization of 444.69 billion HKD [7][16]. Group 2: Financial Performance and Business Development - In the first three quarters of 2024 and 2025, Heng Rui Medicine reported revenues of 27.985 billion yuan and 23.188 billion yuan, representing year-on-year growth of 22.63% and 14.85%, respectively [8][17]. - The net profits for the same periods were 6.337 billion yuan and 5.751 billion yuan, with year-on-year increases of 47.28% and 24.50% [8][17]. - The company achieved significant revenue from its innovative drug business, with sales and licensing income of 9.561 billion yuan in the first half of 2025, accounting for 60.66% of total revenue [9][18]. Group 3: Market Position and Competitive Landscape - Despite strong growth, Heng Rui Medicine faces challenges from competitors, particularly in the innovative drug sector, where it must contend with similar products from other companies [10][21]. - The company’s overseas revenue was approximately 716 million yuan in 2024, constituting only 2.86% of total revenue, highlighting a significant gap compared to competitors like BeiGene, which had over 60% of its revenue from international markets [9][18]. - The oncology segment remains the largest revenue source for Heng Rui Medicine, generating approximately 14.587 billion yuan in 2024, with a gross margin of 92.57% [19][20].